TB Alliance seeks clinical trial waiver for Pretomanid drug

Pretomanid, a new oral treatment is a shorter more convenient option for people with extensively drug resistant (XDR) TB. The dossier for getting approval for the drug has been filed with the drug regulatory authorities. India not only records highest number of TB cases but also bears the maximum burden of XDR TB patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news